GET DAILY SIGNALSWhy Is OptimizeRx Corporation (OPRX) Stock Down -5.41% Today?
Key Takeaways
- OptimizeRx (OPRX) fell 5.41% in early trading, changing hands near $8.39 versus the prior close of $8.87.
- The primary driver remains the company's fiscal 2026 revenue guidance cut to $87–$93 million from $95–$100 million, issued with third-quarter results on November 11.
- A wave of post-earnings price-target reductions from sell-side firms reinforced the cautious tone heading into today's session.
- Part of today's decline reflects a giveback of the violent late-session rebound on November 12 that lifted shares from a $6.33 low back to $8.87.
- Volume is running well below the prior session's heavy turnover, suggesting consolidation rather than fresh institutional selling.
- News Significance Score: 40/100 — Material guidance cut, but the price move was only modestly larger than the stock's normal daily swing.
- Investors can review Price Targets, Earnings history, and Forecast data for deeper context on the setup.
- For systematic, rules-based exposure, explore Trending AI Robots.
Opening Summary
OptimizeRx Corporation (OPRX) is a Waltham, Massachusetts-based digital health technology company whose AI-enabled platform delivers pharmaceutical messaging, copay alerts and clinical information directly into electronic health record and e-prescribing workflows, supplemented by programmatic media and audience-targeting tools. Shares traded at $8.39 on Friday morning, down $0.48, or 5.41%, from the prior session's close of $8.87. The direction is unambiguously lower. The immediate reason is a continuation of the post-earnings repricing triggered on November 11, when management cut its full-year revenue outlook despite beating consensus on both revenue and adjusted EBITDA — followed by a round of analyst price-target reductions and a sharp retracement of the prior day's unusual closing surge.
Post-Earnings Repricing Continues After Guidance Cut
The dominant catalyst remains the third-quarter report released after the closing bell on November 11. Revenue of $21.6 million and non-GAAP earnings of $0.20 per share both topped consensus, and adjusted EBITDA of $6.3 million represented a margin of roughly 29%, up more than 900 basis points year over year. The problem was the top line's trajectory: revenue fell 17% year over year, net revenue retention slipped to 83%, and contracted 2026 revenue is tracking about 20% below the prior year.
Management responded by cutting its fiscal 2026 revenue guidance to $87–$93 million from $95–$100 million, while maintaining adjusted EBITDA guidance of $21–$25 million. Management attributed the revision to the timing of customer spending decisions and limited visibility into fourth-quarter budget buy-ups, rather than any change in the long-term opportunity. For a company with a market capitalization of roughly $168 million and about $99 million in trailing revenue, a reduction of that size is material — the new midpoint sits roughly 8% below the prior midpoint. Shares fell as much as 29% at the open on November 12 before recovering, and the market is still digesting that reset.
Analyst Price-Target Cuts Reinforce the Cautious Tone
Sell-side reaction on November 12 skewed defensive on valuation while staying constructive on rating. Stifel cut its target to $11 from $12, Lake Street moved to $10 from $11, and B. Riley trimmed to $10.50 from $11 — all maintaining Buy ratings. Roth MKM held a $18 target. The consensus stance remains a Strong Buy with an average target near $12.30, but the direction of travel in targets is clearly downward, which has weighed on sentiment as the stock opens a new session.
Retracement of a Violent Late-Day Reversal
A meaningful share of today's weakness is mechanical. On November 12, OptimizeRx opened at $6.70, printed a low of $6.33, then reversed sharply and surged from roughly $7.83 to $8.95 within a single late-afternoon window on more than 120,000 shares, closing at $8.87 — essentially flat on the day. That spike carried the stock far above the levels where it traded for most of the session and left it vulnerable to mean reversion. Today's pullback toward the low-$8s is consistent with the unwinding of that move, reinforced by overnight weakness that took shares as low as $8.05 before the regular session.
Market Context and Trading Activity
Turnover in the early session was light at roughly 7,200 shares, a fraction of the 1.33 million shares that changed hands on November 12 — about seven times the stock's typical daily volume. That combination of heavy prior-session volume and thin follow-through selling points to position cleanup rather than a new wave of institutional distribution. The action was stock-specific, driven by company disclosure and analyst revisions rather than any sector-wide development.
Technically, the pullback pushed shares just below both the 50-day moving average near $8.44 and the 200-day exponential average around $8.48, levels that had acted as support. The stock remains comfortably above its 200-day simple average near $7.18, and the November 12 low of $6.33 now stands as the key near-term floor. The 52-week range spans $4.54 to $16.37, underscoring how wide the band has been.
News Significance Score
The score runs from 0, meaning no meaningful news and a routine move for the stock, to 100, meaning transformative news and an extreme, rare price move. OptimizeRx earns 40 out of 100.
The verified news was substantive: a roughly 8% cut to full-year revenue guidance at the midpoint, paired with a 17% year-over-year revenue decline and deteriorating retention metrics — clearly material relative to a company of this size, though not transformative. The price move was less remarkable. At 5.41%, it was about 2.2 times the stock's typical absolute daily change of roughly 2.4%, and six of the past 60 sessions produced moves of similar or greater magnitude. A common catalyst and an uncommon-but-not-rare move combine into a middling score.
What Comes Next for OPRX
Attention now shifts to the fourth quarter, which carries outsized weight: management noted it is a little over 90% contracted toward the midpoint of guidance, versus mid-90% in prior years, leaving a larger conversion burden in the final weeks of the year. Fourth-quarter and full-year results are expected in early March 2027. Investors will watch whether large pharmaceutical brands release warehoused budgets, whether the returning top-five client scales spending, and how quickly programmatic integrations with DeepIntent, The Trade Desk and PulsePoint convert into recognized revenue.
Management has flagged a 2027 RFP season tracking roughly 20% ahead of last year, alongside a finance leadership transition effective January 1, 2027, when Andy D'Silva becomes CFO. Risks include continued pharma budget scrutiny tied to most-favored-nation pricing policy, customer concentration, and the company's ability to hit the low end of its reduced range. Balanced against that are a debt balance reduced to $10.4 million and an active share repurchase program.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the featured list offers a useful starting point for comparing approaches. Reviewing the current lineup can help traders see which strategies are working in this market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for OPRX shows an upward move is likely
OPRX's Aroon Indicator triggered a bullish signal on November 03, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 125 similar instances where the Aroon Indicator showed a similar pattern. In 108 of the 125 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPRX advanced for three days, in 196 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for OPRX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 16 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 60 cases where OPRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OPRX as a result. In 77 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for OPRX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
OPRX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. OPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.259) is normal, around the industry mean (4.477). P/E Ratio (33.692) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (1.608) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.463) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products
Industry ServicestotheHealthIndustry
Advertisement